COMMUNIQUÉS West-GlobeNewswire

Hennick Humber Hospital Receives Milestone Grant from the Canadian Institutes of Health Research
26/06/2026
TORONTO, June 26, 2026 (GLOBE NEWSWIRE) -- The Research Team at Hennick Humber Hospital (HHH) has been awarded a major research grant from the Canadian Institutes of Health Research (CIHR) as part of a $10 million [...]
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
26/06/2026
WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
26/06/2026
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
Complex Small Molecules Are Changing Drug R&D
26/06/2026
Structural complexity in modern small molecules is reshaping what drug development partners must deliver from discovery through commercial supply. Targeted protein degraders, covalent agents, and a new wave of kinase [...]
CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma
26/06/2026
Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI ® in combination with daratumumab achieved statistically significant improvements in progression-free and overall survival versus [...]
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
26/06/2026
ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today [...]
Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility
26/06/2026
Allschwil, Switzerland – June 26, 2026 Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today confirmed the successful closing of its previously [...]
TerrAscend Completes Oversubscribed Debt Financing, Raising $21.7 Million
25/06/2026
A portion of the proceeds were used to retire existing higher interest rate indebtedness with the remainder available for M&A TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. (the “Company”) (TSX: TSND) ( [...]
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
25/06/2026
Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102 regardless of age or disease severity Rett syndrome natural [...]
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
25/06/2026
COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia [...]
Keros Therapeutics Appoints Anne Prener to its Board of Directors
25/06/2026
LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
25/06/2026
WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx” or the “Company”) today issued the following statement in response to recent public claims made by Kadima [...]
Ligand Announces Closing of Convertible Senior Notes Offering
25/06/2026
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution [...]
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE YEAR 2026 ENDED MARCH 31, 2026
25/06/2026
MINNEAPOLIS, MN, US, June 25, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, [...]
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
25/06/2026
TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its second quarter 2026 financial and operating results on Thursday, July 30, 2026, [...]
DLH Contract Award Opens New Growth Channels with U.S Navy
25/06/2026
ATLANTA, June 25, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital transformation and cybersecurity, systems engineering and integration, and science [...]
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
25/06/2026
LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced [...]
Eikon Therapeutics to Join the Russell 3000® Index
25/06/2026
Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“ [...]
Résultats de l’Assemblée Générale Mixte de Cellectis du 25 juin 2026
25/06/2026
NEW YORK, 25 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome pour développer des [...]

Pages